Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 19,773 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 4,666 · Balance 19,773 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-10 | Direct | 19,188 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 19,188 · Balance 19,188 F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 19,188 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0001193125-26-271157 · ownership.xml · derivative · entry 2 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,188 Underlying: Common Shares · 19,188 shares Expires 2036-06-10 F2 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 4,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-271157 · ownership.xml · nonDerivative · entry 1 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,773 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 75,187 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0000950170-25-086767 · ownership.xml · derivative · entry 1 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,187 Underlying: Common Shares · 75,187 shares Expires 2035-06-11 F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:06 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 16,506 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000950170-24-072427 · ownership.xml · derivative · entry 1 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,506 Underlying: Common Shares · 16,506 shares Expires 2034-06-09 F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:52 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 19,203 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000899243-23-016422 · doc4.xml · derivative · entry 2 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,748 Underlying: Common Shares · 19,203 shares Expires 2033-06-20 F3 · derivative.exercise_date: The shares underlying the option shall vest in twelve (12) equal monthly installments starting from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. F2 · balance_after: On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:52 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 13,671 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016422 · doc4.xml · nonDerivative · entry 1 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,107 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Common Share of the Issuer. The RSUs shall vest in four (4) equal quarterly installments from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. F2 · balance_after: On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 01:19 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 28,628 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034417 · doc4.xml · derivative · entry 5 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,392 Underlying: Subordinate Voting Shares · Not disclosed shares Expires not disclosed F6 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F6 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F6 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F6 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F6 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 01:19 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 717,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034417 · doc4.xml · derivative · entry 4 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759,701 Underlying: Subordinate Voting Shares · Not disclosed shares Expires not disclosed F5 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). F5 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). F5 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). F5 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). F5 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 01:19 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 98,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034417 · doc4.xml · derivative · entry 3 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,962 Underlying: Subordinate Voting Shares · Not disclosed shares Expires not disclosed F4 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 01:19 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 133,744 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-034417 · doc4.xml · derivative · entry 2 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,508 Underlying: Subordinate Voting Shares · 133,744 shares Expires 2017-05-31 F2 · derivative.exercise_price: The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: 8/12ths of the shares underlying the options vested and became exercisable on June 1, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/12th of the total shares vesting on each of June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 01:19 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 21,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034417 · doc4.xml · nonDerivative · entry 1 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,552 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 8/12ths of the RSUs vested and became exercisable on June 1, 2022, with the remaining 4/12ths of the total RSUs vesting on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:08 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 28,628 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034496 · doc4a.xml · derivative · entry 5 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,392 Underlying: Subordinate Voting Shares · Not disclosed shares Expires not disclosed F6 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F6 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F6 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F6 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F6 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:08 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 717,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034496 · doc4a.xml · derivative · entry 4 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759,701 Underlying: Subordinate Voting Shares · Not disclosed shares Expires not disclosed F5 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). F5 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). F5 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). F5 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). F5 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan). Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:08 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 98,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034496 · doc4a.xml · derivative · entry 3 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,962 Underlying: Subordinate Voting Shares · Not disclosed shares Expires not disclosed F4 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:08 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 133,744 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-034496 · doc4a.xml · derivative · entry 2 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,508 Underlying: Subordinate Voting Shares · 133,744 shares Expires 2027-05-31 F2 · derivative.exercise_price: The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: 8/12ths of the shares underlying the options vested and became exercisable on June 1, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/12th of the total shares vesting on each of June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:08 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 21,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034496 · doc4a.xml · nonDerivative · entry 1 Krebs Andreas · CIK 0001438946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,552 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 8/12ths of the RSUs vested and became exercisable on June 1, 2022, with the remaining 4/12ths of the total RSUs vesting on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.